84-1083-84　Vasoactive Intestinal Peptide Receptor Gene Repressor Protein (VIPRRP) 100ul　V2115-18

特徴

• Vasoactive intestinal peptide (VIP) is a 28-aminoacid peptide (human, chr 6q26-q27).
• Expressed and secreted by neurons innervating primary and secondary immune organs such as lymph nodes with a Mol.wt of 20kD.
• VIP is a potent neurotrophic factor causes vasodilation, lowers arterial blood pressure, and relaxes the smooth muscle of trachea, stomach and gall bladder.
• VIP also modulates several T-lymphocyte activities including motility, cytokine production, proliferation and apoptosis, VIP exerts its biological activity by binding to two closely related class II G-protein-coupled receptors VPAC-1 and VPAC-2 beside this VIP has its own receptors VIPR1&2 (Vasoactive Intestinal Polypeptide Receptor 1&2) and VIPRRP (VIP receptor-gene repressor protein).
• VIP shows similarities to glucagon, secretin and gastric inhibitory peptide (GIP) as such it has been considered a member of the glucagon-secretin family.
• The VIP is 100% conserved in mouse, rat and human.
• VIP is considered to be a viable candidate for the development of treatments for rheumatoid arthritis, since treatment with VIP significantly reduced incidence of severity of arthritis, the therapeutic effect of VIP was associated with downregulation of both inflammatory and autoimmune components of the disease
• VIPRRP is a novel transcriptional repressor protein (656aa, rat) that regulates VIPR expression; it encodes a 72kD novel protein that interacts specifically with VIPR repressor element.
• Expression of VIPRRP led to transcriptional repression, thus indicating, positive and negative factors interact with VIPR promoter to regulate its expression.
• The VIPRRP is 78% identical to a previously characterized protein, differentiation-specific element binding protein, which is a member of a family of proteins including components of DNA replication factor C complex.
• Applications:Suitable for use in ELISA, Western Blotting.
• Other applications not tested.
• Recommended Dilution:ELISA: 0.5-1ug/ml.
• Control peptide can be used to coat ELISA plates at 1ug/ml
• Western Blotting: 1-10ug/ml for affinity pure antibody using ECL techniqueOptimal dilutions to be determined by the researcher.
• Storage and Stability:Lyophilized powder may be stored at -20°C.
• Stable for 12 months at -20°C.
• Reconstitute with sterile ddH2O or PBS.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20°C.
• Reconstituted product is stable for 12 months at -20°C.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
• Further dilutions can be made in assay buffer.